Key terms
About CERE
Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy, and Parkinson's disease. Its product candidates include CVL-231, Darigabat, Tavapadon, CVL-871, and CVL-936. The company was founded in 2018 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CERE news
Mar 06
11:56pm ET
Cerevel Therapeutics: Hold Rating Amidst Pending AbbVie Acquisition
Feb 28
5:33am ET
Maintaining Hold Rating Amid ABBV-CERE Deal Progress and Rising Operational Costs
Feb 16
5:04pm ET
Cerevel Therapeutics Advances in Merger Amid FTC Review
Feb 15
6:46am ET
Cerevel Therapeutics price target raised to $45 from $25 at Mizuho
Feb 08
7:33am ET
Neurocrine price target raised to $106 from $100 at Piper Sandler
Jan 22
7:08am ET
Neumora Therapeutics appoints Panandiker as Chief Commercial Officer
Dec 28
5:27am ET
Cerevel Therapeutics price target raised to $45 from $25 at JPMorgan
Dec 26
10:04am ET
Karuna downgraded, Arm target raised: Wall Street’s top analyst calls
Dec 26
6:13am ET
Reviva may be most undervalued in neurology, says H.C. Wainwright
Dec 26
6:06am ET
Maintaining Hold Rating on Cerevel Post-Acquisition by AbbVie: A Fair Value Assessment
Dec 26
6:05am ET
Cerevel Therapeutics price target raised to $45 from $30 at Wells Fargo
Dec 22
4:58am ET
Cerevel Therapeutics downgraded to Hold from Buy at Jefferies
Dec 15
4:22pm ET
Cerevel Therapeutics downgraded to Hold from Buy at Stifel
Dec 15
4:22pm ET
Cerevel Therapeutics just downgraded at Stifel, here’s why
Dec 12
10:43am ET
The biopharma stocks to own in 2024, according to Morgan Stanley
Dec 12
10:43am ET
The biopharma stocks to own in 2024, according to Morgan Stanley
Dec 11
9:25am ET
Cerevel Therapeutics to host conference call
Dec 11
2:10am ET
Analysts Offer Insights on Healthcare Companies: Cooper Co (COO), R1 RCM (RCM) and Cerevel Therapeutics Holdings (CERE)
Dec 10
2:45pm ET
Cerevel Therapeutics to host conference call
Dec 07
5:02pm ET
Cerevel Therapeutics just downgraded at TD Cowen, here’s why
Dec 07
4:40pm ET
Analysts Conflicted on These Healthcare Names: Cerevel Therapeutics Holdings (CERE) and Alector (ALEC)
Dec 07
12:15pm ET
Cautious Hold Rating on Cerevel Amidst Acquisition by AbbVie
Dec 07
12:09pm ET
Cerevel Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Dec 07
12:00pm ET
After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next
Dec 07
12:00pm ET
After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next
Dec 07
8:10am ET
Analysts Are Bullish on Top Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN), Cerevel Therapeutics Holdings (CERE)
Dec 07
5:15am ET
Cerevel Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Dec 07
5:12am ET
Cerevel Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
No recent press releases are available for CERE
CERE Financials
Key terms
Ad Feedback
CERE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CERE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
